Article
p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
JCI insight - 8 Oct 2021
Man Na, Mas Gloria, Karl Daniel L, Sun Jun, Liu Fan, Yang Qin, Torres-Martin Miguel, Itonaga Hidehiro, Martinez Concepcion, Chen Shi, Xu Ye, Duffort Stephanie, Hamard Pierre-Jacques, Chen Chuan, Zucconi Beth E, Cimmino Luisa, Yang Feng-Chun, Xu Mingjiang, Cole Philip A, Figueroa Maria E, Nimer Stephen D
Abstract excerpt
Myelodysplastic syndromes (MDS) are hematopoietic stem and progenitor cell (HSPC) malignancies characterized by ineffective hematopoiesis and an increased risk of leukemia transformation. Epigenetic regulators are recurrently mutated in MDS, directly implicating epigenetic dysregulation in MDS pathogenesis. Here, we identified a tumor suppressor role of the acetyltransferase p300 in clinically relevant MDS models...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.